Caring for Vision | Yeedozencom helps pharmaceutical companies promote ophthalmic drug clinical trials
October of each year is not only the season when the autumn wind is refreshing, but also the season when the world emphasizes caring for vision. Under the "Vision 2020 Global Initiative", the second Thursday of October each year is designated "World Vision Day." A series of activities to protect vision are organized by the IAPB (International Agency for the Prevention of Blindness), and the Vision Impact Institute and the Global Vision Organization jointly emphasize the need for good vision.
Myopia is the most common eye disease in children and a very serious global public health problem. According to the data released by the Health Commission in 2018, the prevalence of myopia in pupils in China has increased to 36%, 71.6% in junior high school students and 81% in high school students. Myopia not only affects the quality of daily life, but also may lead to serious complications such as retinal detachment, macular degeneration, glaucoma and cataract and endanger visual health. Epidemiological surveys in recent years in China have found that myopic retinopathy has become the first irreversible blinding eye disease in China.
Yeedozencom is helping pharmaceutical companies promote ophthalmic drug clinical trials and delay the progression of myopia in children. Atropine ophthalmic preparations have been used clinically to delay the progression of myopia in children for decades, and atropine sulfate eye drops can be used to delay the progression of myopia in children.
The clinical trial project has been carried out in hospitals/clinical research centers in Wenzhou, Hangzhou, Shanghai, Guangzhou, Beijing, Chengdu, Tianjin, Nanjing, Wuhan, Xi'an, Zhengzhou, Qingdao, Xuzhou, Wuxi and Hefei. If you/your child meet the conditions for participating in the clinical trial, you are also willing to join us to help the prevention and treatment of myopia in children. Welcome to contact us for more information about this clinical trial.
Information of partially initiated clinical sites:
Wenzhou: https://u12660459.viewer.maka.im/k/CXND0KZGW12660459
Tianjin: https://u11448618.viewer.maka.im/k/47GGNE5UW11448618
Wuhan: https://u12211631.viewer.maka.im/k/Z56LQN3MW12211631?hash=3cd100e67770c2ffffcbce9afddd8c1c
Beijing: https://u12211631.viewer.maka.im/k/MT7AQ72DW12211631?time=1602227896892
Henan:https://u12842465.viewer.maka.im/k/TBV3TYISW12842465?hash=8f736f7a1044f2de9d475518755f82c9
Step-by-step activation of clinical sites in other regions
For details, please consult: 025-69517007 (Manager)
yujia@yeedo.com.cn
